logo
Plus   Neg
Share
Email

Genentech: Tecentriq, Avastin Combination Study Meets Co-primary Endpoints

Genentech, a member of the Roche Group (RHHBY), said Tecentriq in combination with Avastin, as a treatment for people with unresectable hepatocellular carcinoma who have not received prior systemic therapy, showed statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared with standard-of-care sorafenib in a Phase III IMbrave150 study. Safety data for the combination was consistent with the safety profiles of the individual medicines.

In July 2018, the U.S. FDA granted Breakthrough Therapy Designation for Tecentriq in combination with Avastin in hepatocellular carcinoma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
SCARPA North America has recalled about 4,200 ski boots due to risk of fall. The company has recalled Maestrale RS and Maestrale Men's ski boots as its shell can crack, posing a fall hazard and risk of injury to the consumer. The recall involves the Fall 2017 Maestrale RS and Maestrale Men's Ski... Walt Disney's (DIS) Frozen 2, the sequel to its 2013 blockbuster, is expected to record a strong domestic opening of over $100 million this weekend. Frozen 2 will become the 10th animated film to debut with over $100 million and the first animated film outside the summer window to hit the mark. Frozen... Indonesia is exploring a total ban on the use of electronic cigarettes and vape products in the country due to healthcare concerns following the lung illness outbreak related to vaping in the U.S., according to reports. However, the South-East Asian country has not reported any cases of vaping-related illness. Chain-smoking Indonesia is the world's second largest tobacco market.
Follow RTT
>